Recombitek C8 - 47K9.R0

Verify with FDA CVM →

206 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
206
Total Reports
19
Deaths Reported
920.0%
Death Rate

Active Ingredients

Recombitek C8 - 47K9.R0

Administration Routes

SubcutaneousUnknownOral

Species Affected

Dog 206

Most Affected Breeds

Retriever - Labrador 16
Shih Tzu 15
Retriever - Golden 14
Chihuahua 10
Shepherd Dog - Australian 9
Pit Bull 9
Dachshund (unspecified) 9
Shepherd Dog - German 9
Spaniel - King Charles Cavalier 7
Terrier - Yorkshire 7

Most Reported Reactions

Vomiting 49
Injection site pain 34
Diarrhoea 23
Injection site swelling 22
Lethargy (see also Central nervous system depression in 'Neurological') 22
Lethargy (see also Central nervous system depression in Neurological) 21
Injection site lump 20
Anorexia 15
Seizure NOS 14
Pain NOS 13
Death 12
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 11

Outcome Breakdown

Outcome Unknown
88 (42.5%)
Recovered/Normal
80 (38.6%)
Ongoing
20 (9.7%)
Died
12 (5.8%)
Euthanized
7 (3.4%)

Data Summary

Metric Value
Total adverse event reports 206
Reports involving death 19
Case-fatality rate (reported events) 920.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Recombitek C8 - 47K9.R0 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 206 adverse event reports referencing Recombitek C8 - 47K9.R0, including 19 reports in which the animal died — a 920.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Recombitek C8 - 47K9.R0. Reported administration routes include Subcutaneous, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Recombitek C8 - 47K9.R0 reports are Dog (206 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (16), Shih Tzu (15), Retriever - Golden (14) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Recombitek C8 - 47K9.R0 are Vomiting (49), Injection site pain (34), Diarrhoea (23), Injection site swelling (22). Of the 207 reports with a coded outcome, Outcome Unknown is the leading category at 42.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Recombitek C8 - 47K9.R0.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial